Sands BE, Clemow DB, D'Haens G, Irving PM, et al. Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study. Inflamm Bowel Dis 2026 Mar 2:izag007. doi: 10.1093.
PMID: 41777218